查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1243851

男性性腺功能低下症的全球市场

Male Hypogonadism
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

男性性腺功能低下症的全球市场2030年前将达到54亿美元

在COVID-19后改变的商务环境中，2022年37亿美元的男性性腺功能低下症的全球市场，2030年前将达到54亿美元的规模，在2022年～2030年预计将以年复合成长率5.1％增长。本报告所分析之市场区隔之一的睪酮替代疗法年复合成长率将记录4.9％，到分析期间结束时将达到32亿美元。考虑疫情后的復苏，促性腺激素分泌/促性腺激素释放激素治疗领域今后8年的年复合成长率将修正为5.3％。

美国市场估算为11亿美元，中国则将以年复合成长率4.8％成长预测

美国的男性性腺功能低下症市场在2022年估算为11亿美元。作为世界第2大经济大国的中国，在2022年～2030年年复合成长率预计将为4.8％，2030年前将达到9亿6,250万美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以4.7％和4.2％的速度成长。在欧洲市场中，德国以年复合成长率约4.9％成长。

调查对像企业范例

  • AbbVie, Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Endo International PLC
  • Ferring International Center SA
  • IBSA Institut Biochimique SA
  • Laboratoires Genevrier
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP13151

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Male Hypogonadism Market to Reach $5.4 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Male Hypogonadism estimated at US$3.7 Billion in the year 2022, is projected to reach a revised size of US$5.4 Billion by 2030, growing at aCAGR of 5.1% over the period 2022-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is projected to record 4.9% CAGR and reach US$3.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is readjusted to a revised 5.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 4.8% CAGR

The Male Hypogonadism market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$962.5 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 4.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Select Competitors (Total 47 Featured) -

  • AbbVie, Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Endo International PLC
  • Ferring International Center SA
  • IBSA Institut Biochimique SA
  • Laboratoires Genevrier
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Male Hypogonadism - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Male Hypogonadism Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Topical Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Transdermal Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Delivery Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Delivery Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Delivery Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pituitary Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pituitary Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pituitary Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Klinefelters Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Klinefelters Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Klinefelters Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Kallmann Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Kallmann Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: World 16-Year Perspective for Kallmann Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Disorder Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Disorder Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Disorder Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • JAPAN
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • CHINA
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: China 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: China 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: China 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • EUROPE
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • FRANCE
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: France 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: France 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: France 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • GERMANY
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2023 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2023 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2023 & 2030

IV. COMPETITION